Home
Laboratories
Laboratory Profile
  1. Augmenting the differentiation, maturation, survival, function and the immune tolerance of human stem cell-derived insulin-producing beta cells
  2. The evaluation of the immunogenicity of and/or immune responses to clinical grade alginate microbeads across different species including mice, rats, non-human primates and humans.
  3. The use of novel chemokines as immunomodulatory agents to prevent the occurrence of post- operative abdominal adhesion formation
  1. David A. Alagpulinsa, BPharm PhD, Research Fellow, MGH & Harvard Medical School
  1. Riley Driscoll, BS Candidate, Brigham Young University, Utah, USA.
  2. Jenny Cao, BA, MB ChB Candidate, University of Cambridge, Cambridge, UK.
JOURNAL PUBLICATIONS
  1. Alagpulinsa, DA. , Ayyadevara, S., Yaccoby, S. & Shmookler Reis, R. J. A cyclin-dependent kinase inhibitor, dinaciclib, impairs homologous recombination and sensitizes multiple myeloma cells to PARP inhibition. Molecular Cancer Therapeutics, 2015, 15(2); 1-10.
  2. Alagpulinsa DA, Yaccoby S, Ayyadevara S and Shmookler Reis RJ. A peptide nucleic acid targeting nuclear Rad51 sensitizes multiple myeloma cells to melphalan treatment. Cancer Biology and Therapy, 2015; 16(6): 976-986.
  3. Alagpulinsa DA, Ayyadevara S, Shmookler Reis RJ. A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. Frontiers in Oncology, 2014;4(289).
  4. Woode E, Alagpulinsa DA and Abotsi WKM. Anti-nociceptive, anxiolytic and anticonvulsant effects of an aqueous leaf extract of Leea guineensis G. Don (Family: Leeaceae). African Journal of Pharmacy and Pharmacology , 2011, 5:1132-1144.
PEER-REVIEWED, PUBLISHED CONFERENCE PAPERS/ABSTRACTS
  1. Shammas MA, Buon L, Kumar S, Samur SK, Alagpulinsa DA, Nanjappa P and Nikhil C Munshi. 'Flap Structure-Specific Endonuclease 1 (FEN1) May be a Key Mediator of Genome Instability in Myeloma: A Cellular Vulnerability with Potential Therapeutic Significance ' Blood 2016 128:4440.
  2. Shammas MA, Buon L, Lin L, Samur MK, Patel JM, Vahia A, Nanjappa P, Kumar S, Bajwa A, Ahmad H, Alagpulinsa DA , Parmigiani G, Magrangeas F, Minvielle S, Avet-Loiseau H and Munshi NC ' Nuclease Activity Is Associated with Genomic Instability as Well As Survival in Myeloma; Underlying Mechanisms and Significance'. Blood 2015 126:2420;
  3. Alagpulinsa DA, Ayyadevara S, Yaccoby S, and Shmookler Reis RJ. Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Blood, 2014, 124:479-479.
  4. Alagpulinsa DA, Ayyadevara S, Yaccoby S and Shmookler Reis RJ (2014) A Peptide Nucleic Acid Targeting Nuclear Rad51 Sensitizes Myeloma Cells to Melphalan Chemotoxicity Both in Vitro and in Vivo. Blood, 124:3529-3529.
  5. Alagpulinsa DA, Yaccoby S, Ayyadevara S, Reis RJS. Abstract 2400: Dinaciclib, an inhibitor of cyclin- dependent kinases (CDKs), impairs homologous recombination, abrogates G2 checkpoint arrest and sensitizes myeloma cells to PARP inhibition. Cancer Research 2014; 74(19 Supplement): 2400